Evolva Holding SA

Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected

Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected

Approval of temporary exemption from certain conditions for maintaining listing pursuant to art. 7 Listing Rules

Approval of temporary exemption from certain conditions for maintaining listing pursuant to art. 7 Listing Rules

Evolva Holding in liquidation SA publishes liquidation interim financial statements and agenda for 2024 annual general meeting; reports positive purchase price adjustment of CHF 1,929,000 under SPA; g

Evolva Holding in liquidation SA publishes liquidation interim financial statements and agenda for 2024 annual general meeting; reports positive purchase price adjustment of CHF 1,929,000 under SPA

Evolva Holding SA in liquidation: Nice & Green requests 3 agenda items be included in AGM agenda

Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG on 28 December 2023

Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting

Evolva convenes extraordinary general meeting (EGM) for 21 December 2023 to approve the sale of Evolva AG to Lallemand Inc.

Evolva enters into an agreement to sell its operations to Lallemand, securing the best possible outcome for the company and its stakeholders

Evolva and Breko broaden partnership by signing agreement for the exclusive distribution of Veri-teTM Resveratrol in Germany, Austria, Thailand and Vietnam

Evolva and LEHVOSS sign agreement for distribution of Veri-teTM Resveratrol in over a dozen European countries

Evolva and Nice & Green agree on improvements to financing agreement

Evolva receives approval for Veri-teTM Resveratrol in Thailand

Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023

Evolva with good business momentum and significant progress in profitability in 1H 2023, despite major financing challenges

Evolva Holding SA: Evolva convenes extraordinary general meeting (EGM) for 24 August 2023 to secure financing until end of the year

Evolva receives approval for Veri-teTM Resveratrol in Taiwan

Evolva Holding SA: Evolva signs agreement with Nice & Green to secure financing at least until the end of 2023, continues to pursue strategic alternatives

Evolva informs about renegotiation of financing arrangement, initiates review of strategic alternatives and revokes guidance

Evolva signs multi-year agreement with leading CMO partner to enable supply of Vanillin to global F&F customer of around CHF 35 million until 2026

Evolva publishes timeline of the Reverse Stock Split

Evolva shareholders approve all motions proposed by the Board at today’s Annual General Meeting

Evolva goes Responsible Care at in-cosmetics 2023

Evolva publishes agenda for 2023 Annual General Meeting

Evolva delivers accelerated revenue growth of 57% in 2022 and substantially improved profitability profile

Evolva partners with Grace Breeding to replace chemical fertilizers with nature-based alternative

Evolva delivers strong results with 57% revenue growth and increasing margins

Evolva launches its Natural Nootkatone